Description
A hypoxia-activated prodrug and DNA alkylating agent with anticancer activity; selectively cytotoxic to H460 human NSCLC cells grown under hypoxic over normoxic conditions (IC50s = 0.019 and 5.1 μM, respectively); reduces survival of H460 and HT-29 cells in a clonogenic assay (IC50s = 0.2 and 0.2 μM, respectively); inhibits primary tumor growth by 41% in an MIA PaCa-2-RFP mouse orthotopic xenograft model at 33 mg/kg per day; inhibits tumor growth in the Calu-6 NSCLC, H82 small cell lung, A375 melanoma, PC-3 prostate, and BxPC-3 pancreatic cancer mouse xenograft models at 50 mg/kg
Formal name: N,N’-bis(2-bromoethyl)-phosphorodiamidic acid, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester
Synonyms: Evofosfamide
Molecular weight: 449
CAS: 918633-87-1
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|DNA Alkylating Agents||Research Area|Cancer|Cell Death||Research Area|Cancer|DNA Damage and Repair|DNA Alkylating Agents||Research Area|Cancer|Tumor Microenvironment